Aridis Financial Statements From 2010 to 2025
| ARDS Stock | USD 0 0 650.00% |
Check Aridis Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aridis Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Aridis financial statements analysis is a perfect complement when working with Aridis Pharmaceuticals Valuation or Volatility modules.
Aridis |
Aridis Pharmaceuticals Company Shares Owned By Insiders Analysis
Aridis Pharmaceuticals' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Aridis Pharmaceuticals Shares Owned By Insiders | 31.53 % |
Most of Aridis Pharmaceuticals' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aridis Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 31.53% of Aridis Pharmaceuticals are shares owned by insiders. This is 107.71% higher than that of the Biotechnology sector and 122.36% higher than that of the Health Care industry. The shares owned by insiders for all United States stocks is notably lower than that of the firm.
Aridis Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Aridis Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Aridis Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aridis Pharmaceuticals competition to find correlations between indicators driving Aridis Pharmaceuticals's intrinsic value. More Info.Aridis Pharmaceuticals is rated below average in return on asset category among its peers. It is rated fifth in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Aridis Pharmaceuticals' earnings, one of the primary drivers of an investment's value.About Aridis Pharmaceuticals Financial Statements
Aridis Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Aridis Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Aridis Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Aridis Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California. Aridis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 34 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aridis Pink Sheet Analysis
When running Aridis Pharmaceuticals' price analysis, check to measure Aridis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aridis Pharmaceuticals is operating at the current time. Most of Aridis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aridis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aridis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aridis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.